This, in turn, reduces the effectiveness of immune checkpoint inhibitors, such as anti-PD-1 and anti-PD-L1 antibodies, highlighting METTL14’s central role in immune resistance in liver cancer (30, 31). Here, METTL14 is linked to liver cancer.